Fresenius Medical Care AG: Form 20-F for the period ended Dec 31, 2016
Filed with the SEC on Feb 22, 2017 and accepted by EDGAR at Feb 22, 2017, 11:20 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2016-01-01 to 2016-12-31 | $12.13bn | us-gaap:CostOfRevenue |
| Gross profit | 12 months2016-01-01 to 2016-12-31 | $5.78bn | us-gaap:GrossProfit |
| Research and development | 12 months2016-01-01 to 2016-12-31 | $162.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2016-01-01 to 2016-12-31 | $3.04bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2016-01-01 to 2016-12-31 | $2.64bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2016-01-01 to 2016-12-31 | $452.2m | us-gaap:InterestExpense |
| Income tax | 12 months2016-01-01 to 2016-12-31 | $683.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2016-01-01 to 2016-12-31 | $1.24bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2016-01-01 to 2016-12-31 | $4.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2016-01-01 to 2016-12-31 | $4.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2016-01-01 to 2016-12-31 | 306,257,744 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2016-01-01 to 2016-12-31 | $2.14bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2016-01-01 to 2016-12-31 | $1.03bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2016-01-01 to 2016-12-31 | −$277.2m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2016-12-31 | $747.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-12-31 | $7.31bn | us-gaap:AssetsCurrent |
| Total assets | At period end2016-12-31 | $26.93bn | us-gaap:Assets |
| Current liabilities | At period end2016-12-31 | $5.04bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-12-31 | $14.24bn | us-gaap:Liabilities |
| Long-term debt | At period end2016-12-31 | $7.20bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2016-12-31 | $605.7m | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2016-12-31 | $602.5m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2016-12-31 | $10.81bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2016-12-31 | 306,221,840 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001047469-17-000816. Last ingested by Listed: Nov 3, 2026, 10:24 ET. Listed shows no prices and gives no investment advice.